 | Up a level |
Kluemper, Niklas, Ralser, Damian J., Zarbl, Romina, Schlack, Katrin, Schrader, Andres Jan, Rehlinghaus, Marc, Hoffmann, Michele J., Niegisch, Guenter, Uhlig, Annemarie, Trojan, Lutz, Steinestel, Julie, Steinestel, Konrad, Wirtz, Ralph M., Sikic, Danijel, Eckstein, Markus, Kristiansen, Glen, Toma, Marieta, Hoelzel, Michael, Ritter, Manuel, Strieth, Sebastian, Ellinger, Joerg and Dietrich, Dimo (2021). CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J. Immunother. Cancer, 9 (8). LONDON: BMJ PUBLISHING GROUP. ISSN 2051-1426